Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Newcastle University | OTHER |
| Teesside University | OTHER |
| Versus Arthritis | OTHER |
Not provided
Not provided
Not provided
Not provided
This study investigates the feasibility of a fully remote effectiveness evaluation of a self-management smartphone application for those with Sjogren's syndrome.
The aim of this study is to pilot and assess the feasibility of a fully remote effectiveness evaluation of a smartphone self-management app for those living with Sjogren's syndrome.
The fully-remote evaluation will involve minimal contact with researchers. Potential participants will be recruited internationally online through social media and mailing lists for Sjogren's syndrome support groups. Adverts will direct people to download the self-management app on app stores (Apple App Store and Google Play). The app has been designed to automate all study procedures, by guiding users through the following processes: screening, informed consent, randomisation, and the collection of outcome data through in-app surveys sent at 0, 5, and 10 weeks. Users will be randomised to receive the full intervention or a control:
To pilot and assess the feasibility of the planned methodology, and inform the design of a future definitive randomised control trial of the app, the primary objectives of this study are to: characterise users (i.e. international recruitment and consent rates), and test screening, randomisation and data collection procedures (i.e. outcome measure completion rates and score variability). The secondary objectives are to explore app engagement patterns (using log data) and the acceptability of the study procedures and the app (using remote semi-structured interviews).
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Full app with all app components | Experimental | Users receive app that contains all intervention components including: Symptom and Lifestyle information, Energy management, Goal Setting, Managing Difficult Times, Assertiveness and Communication Skills. |
|
| Control minimal app with information component only | Active Comparator | Users receive app that contains only Symptom and Lifestyle information, and cannot see other intervention components. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Self-management app with all intervention components | Behavioral | A behavioural self-management app, containing multiple cognitive- and behavioural self-management techniques for those living with Sjögren's syndrome. The intervention is comprised of several components and modules that holistically target several key symptoms: fatigue, sleep disturbances, chronic pain, and dryness. The app has been developed using user-centred methods, and is theory- and evidence-based. |
| Measure | Description | Time Frame |
|---|---|---|
| Number of people downloading the app | Total number of people who download the app from App Stores | Through to completion of data collection period of up to 6 months |
| Percentage of eligible users (denominator is number downloading) | Proportion of users who have downloaded the app that are eligible to participate | Through to completion of data collection period up to 6 months |
| Percentage of consenting users (denominator is number eligible) | Proportion of those who are eligible to participate that consented to take part in the study | Through to completion of data collection period up to 6 months |
| Percentage of randomised users (denominator is number eligible) | Proportion of those who are eligible to participate that complete all surveys at week 0 and then automatically randomised to one of two app versions. | Through to completion of data collection period up to 6 months |
| Percentage of retained users (denominator is number consenting) at 5 weeks | Proportion of those who those who consent to participate that complete all surveys at 5 weeks | Through to completion of data collection period up to 6 months |
| Percentage of retained users (denominator is number consenting) at 10 weeks | Proportion of those who those who consent to participate that complete all surveys at 10 weeks | Through to completion of data collection period up to 6 months |
| Measure | Description | Time Frame |
|---|---|---|
| App user retention | Percentage of participants who launch the app at least once a week as recorded by automatically-generated logs | Interaction data will be collected continuously for up to 13 weeks for each participant. |
| Frequency of app engagement |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Katie L Hackett, PhD | Northumbria University | Principal Investigator |
| Claire H McCallum, PhD | Northumbria University | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Northumbria University | Newcastle upon Tyne | Tyne and Wear | NE7 7YR | United Kingdom |
Data sets (including answers to questionnaires, smartphone interaction data, and qualitative interview data) may be used to support future student projects at Northumbria University, however these datasets will be fully anonymised before being shared.
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D012859 | Sjogren's Syndrome |
| ID | Term |
|---|---|
| D001172 | Arthritis, Rheumatoid |
| D001168 | Arthritis |
| D007592 | Joint Diseases |
| D009140 | Musculoskeletal Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
|
| Self-management app with Information component only | Behavioral | self-management app for those with Sjögren's syndrome, includes Symptom and Lifestyle Information, only. |
|
|
| ICECAP-A Completion rate (denominator is number consenting) at 0 weeks |
Percentage of those who consent to take part that complete all 5 questions of ICECAP-A survey |
| 0 weeks from date of consent |
| ICECAP-A Completion rate (denominator is number consenting) at 5 weeks | Percentage of those who consent to take part that complete all 5 questions of ICECAP-A survey | 5 weeks from date of consent |
| ICECAP-A Completion rate (denominator is number consenting) at 10 weeks | Percentage of those who consent to take part that complete all 5 questions of ICECAP-A survey | 10 weeks from date of consent |
| ICECAP-A Mean Score at 0 weeks | Average score on "ICECAP-A" Quality of Life Measure across participants | 0 weeks from date of consent |
| ICECAP-A Mean Score at 5 weeks | Average score on "ICECAP-A" Quality of Life Measure across participants | 5 weeks from date of consent |
| ICECAP-A Mean Score at 10 weeks | Average score on "ICECAP-A" Quality of Life measure across participants | 10 weeks from date of consent |
| ICECAP-A Standard Deviation of Mean Score at 0 weeks | Standard deviation around Mean Score on "ICECAP-A" Quality of Life Measure across participants | 0 weeks from date of consent |
| ICECAP-A Standard Deviation of Mean Score at 5 weeks | Standard deviation around Mean Score on "ICECAP-A" Quality of Life Measure across participants | 5 weeks from date of consent |
| ICECAP-A Standard Deviation of Mean Score at 10 weeks | Standard deviation around Mean Score on "ICECAP-A" Quality of Life Measure across participants | 10 weeks from date of consent |
| ESSPRI Completion Rate (denominator is number consenting) at 0 weeks | Percentage of those who consent to take part that complete all 3 questions of ESSPRI symptom severity survey (assessing dryness, fatigue and pain symptoms). | 0 weeks from date of consent |
| ESSPRI Completion Rate (denominator is number consenting) at 5 weeks | Percentage of those who consent to take part that complete all 3 questions of ESSPRI survey (assessing dryness, fatigue and pain symptoms). | 5 weeks from date of consent |
| ESSPRI Completion Rate (denominator is number consenting) at 10 weeks | Percentage of those who consent to take part that complete all 3 questions of ESSPRI symptom severity survey (assessing dryness, fatigue and pain symptoms). | 10 weeks from date of consent |
| ESSPRI Mean Score at 0 weeks | Average score on "ESSPRI" symptom severity measure across participants | 0 weeks from date of consent |
| ESSPRI Mean Score at 5 weeks | Average score on "ESSPRI" symptom severity measure across participants | 5 weeks from date of consent |
| ESSPRI Mean Score at 10 weeks | Average score on "ESSPRI" symptom severity measure across participants | 10 weeks from date of consent |
| ESSPRI Standard Deviation of Mean Score at 0 weeks | Standard deviation around Mean Score on ESSPRI symptom severity measure across participants | 0 weeks from date of consent |
| ESSPRI Standard Deviation of Mean Score at 5 weeks | Standard deviation around Mean Score on ESSPRI symptom severity measure across participants | 5 weeks from date of consent |
| ESSPRI Standard Deviation of Mean Score at 10 weeks | Standard deviation around Mean Score on ESSPRI symptom severity measure across participants | 10 weeks from date of consent |
| MFIS-5 Completion Rate (denominator is number consenting) at 0 weeks | Percentage of those who consent to take part that complete all 5 questions of the Modified Fatigue Impact Scale | 0 weeks from date of consent |
| MFIS-5 Completion Rate (denominator is number consenting) at 5 weeks | Percentage of those who consent to take part that complete all 5 questions of the Modified Fatigue Impact Scale | 5 weeks from date of consent |
| MFIS-5 Completion Rate (denominator is number consenting) at 10 weeks | Percentage of those who consent to take part that complete all 5 questions of the Modified Fatigue Impact Scale | 10 weeks from date of consent |
| MFIS-5 Mean Score at 0 weeks | Average score on the MFIS-5 fatigue impact measure, across participants | 0 weeks from date of consent |
| MFIS-5 Mean Score at 5 weeks | Average score on the MFIS-5 fatigue impact measure, across participants | 5 weeks from date of consent |
| MFIS-5 Mean Score at 10 weeks | Average score on the MFIS-5 fatigue impact measure, across participants | 10 weeks from date of consent |
| MFIS-5 Standard Deviation of Mean Score at 0 weeks | Standard deviation around Mean Score on MFIS-5 fatigue impact measure across participants | 0 weeks from date of consent |
| MFIS-5 Standard Deviation of Mean Score at 5 weeks | Standard deviation around Mean Score on MFIS-5 fatigue impact measure across participants | 5 weeks from date of consent |
| MFIS-5 Standard Deviation of Mean Score at 10 weeks | Standard deviation around Mean Score on MFIS-5 fatigue impact measure across participants | 10 weeks from date of consent |
| Depression Digital Visual Analogue Scale (VAS) Completion Rate (denominator is number consenting) at 0 weeks | Percentage of those who consent to take part that complete the single digital VAS regarding severity of depression | 0 weeks from date of consent |
| Depression Digital Visual Analogue Scale (VAS) Completion Rate (denominator is number consenting) at 5 weeks | Percentage of those who consent to take part that complete the single digital VAS regarding severity of depression | 5 weeks from date of consent |
| Depression Digital Visual Analogue Scale (VAS) Completion Rate (denominator is number consenting) at 10 weeks | Percentage of those who consent to take part that complete the single digital VAS regarding severity of depression | 10 weeks from date of consent |
| Depression Digital Visual Analogue Scale (VAS) Mean Score at 0 weeks | Average score on the 100 point digital VAS across participants | 0 weeks from date of consent |
| Depression Digital Visual Analogue Scale (VAS) Mean Score at 5 weeks | Average score on the 100 point digital VAS across participants | 5 weeks from date of consent |
| Depression Digital Visual Analogue Scale (VAS) Mean Score at 10 weeks | Average score on the 100 point digital VAS across participants | 10 weeks from date of consent |
| Depression Digital VAS Standard Deviation of Mean Score at 0 weeks | Standard deviation around Mean Score on depression VAS across participants | 0 weeks from date of consent |
| Depression Digital VAS Standard Deviation of Mean Score at 5 weeks | Standard deviation around Mean Score on depression VAS across participants | 5 weeks from date of consent |
| Depression Digital VAS Standard Deviation of Mean Score at 10 weeks | Standard deviation around Mean Score on depression VAS across participants | 10 weeks from date of consent |
| Anxiety Digital Visual Analogue Scale (VAS) Completion Rate (denominator is number consenting) at 0 weeks | Percentage of those who consent to take part that complete the single digital VAS regarding severity of anxiety | 0 weeks from date of consent |
| Anxiety Digital Visual Analogue Scale (VAS) Completion Rate (denominator is number consenting) at 5 weeks | Percentage of those who consent to take part that complete the single digital VAS regarding severity of anxiety | 5 weeks from date of consent |
| Anxiety Digital Visual Analogue Scale (VAS) Completion Rate (denominator is number consenting) at 10 weeks | Percentage of those who consent to take part that complete the single digital VAS regarding severity of anxiety | 10 weeks from date of consent |
| Anxiety Digital VAS Mean Score at 0 weeks | Average score on the 100 point digital VAS across participants | 0 weeks from date of consent |
| Anxiety Digital VAS Mean Score at 5 weeks | Average score on the 100 point digital VAS across participants | 5 weeks from date of consent |
| Anxiety Digital VAS Mean Score at 10 weeks | Average score on the 100 point digital VAS across participants | 10 weeks from date of consent |
| Anxiety Digital VAS Standard Deviation of Mean Score at 0 weeks | Standard deviation around Mean Score on the Anxiety digital VAS across participants | 0 weeks from date of consent |
| Anxiety Digital VAS Standard Deviation of Mean Score at 5 weeks | Standard deviation around Mean Score on the Anxiety digital VAS across participants | 5 weeks from date of consent |
| Anxiety Digital VAS Standard Deviation of Mean Score at 10 weeks | Standard deviation around Mean Score on the Anxiety digital VAS across participants | 10 weeks from date of consent |
| Sleep Condition Index (SCI) Completion Rate (denominator is number consenting) at 0 weeks | Percentage of those who consent to take part that complete all 8 questions of the SCI | 0 weeks from date of consent |
| Sleep Condition Index (SCI) Completion Rate (denominator is number consenting) at 5 weeks | Percentage of those who consent to take part that complete all 8 questions of the SCI | 5 weeks from date of consent |
| Sleep Condition Index (SCI) Completion Rate (denominator is number consenting) at 10 weeks | Percentage of those who consent to take part that complete all 8 questions of the SCI | 10 weeks from date of consent |
| Sleep Condition Index (SCI) Mean Score at 0 weeks | Average score on the SCI across participants | 0 weeks from date of consent |
| Sleep Condition Index (SCI) Mean Score at 5 weeks | Average score on the SCI across participants | 5 weeks from date of consent |
| Sleep Condition Index (SCI) Mean Score at 10 weeks | Average score on the SCI across participants | 10 weeks from date of consent |
| Sleep Condition Index (SCI) Standard Deviation of Mean Score at 0 weeks | Standard deviation around Mean Score on the SCI across participants | 0 weeks from date of consent |
| Sleep Condition Index (SCI) Standard Deviation of Mean Score at 5 weeks | Standard deviation around Mean Score on the SCI across participants | 5 weeks from date of consent |
| Sleep Condition Index (SCI) Standard Deviation of Mean Score at 10 weeks | Standard deviation around Mean Score on the SCI across participants | 10 weeks from date of consent |
| PAM-10 Completion Rate (denominator is number consenting) at 0 weeks | Percentage of those who consent to take part that complete all 10 questions of the Patient Activation Measure (PAM-10) | 0 weeks from date of consent |
| PAM-10 Completion Rate (denominator is number consenting) at 5 weeks | Percentage of those who consent to take part that complete all 10 questions of the Patient Activation Measure (PAM-10) | 5 weeks from date of consent |
| PAM-10 Completion Rate (denominator is number consenting) at 10 weeks | Percentage of those who consent to take part that complete all 10 questions of the Patient Activation Measure (PAM-10) | 10 weeks from date of consent |
| PAM-10 Mean Score at 0 weeks | Average score on the PAM-10 across participants | 0 weeks from date of consent |
| PAM-10 Mean Score at 5 weeks | Average score on the PAM-10 across participants | 5 weeks from date of consent |
| PAM-10 Mean Score at 10 weeks | Average score on the PAM-10 across participants | 10 weeks from date of consent |
| PAM-10 Standard Deviation of Mean Score at 0 weeks | Standard deviation around Mean Score on the PAM-10 across participants | 0 weeks from date of consent |
| PAM-10 Standard Deviation of Mean Score at 5 weeks | Standard deviation around Mean Score on the PAM-10 across participants | 5 weeks from date of consent |
| PAM-10 Standard Deviation of Mean Score at 10 weeks | Standard deviation around Mean Score on the PAM-10 across participants | 10 weeks from date of consent |
| User Demographics | Investigator-developed questionnaire asking users to enter their gender (M/F/Other/Prefer not to say), age (years), whether users have primary or secondary Sjogren's syndrome, number of years since diagnosis, country of residence, and any other conditions users wish to report. | 0 weeks from date of consent |
The maximum, minimum and average number of times the app is launched
| Interaction data will be collected continuously for up to 13 weeks for each participant. |
| Duration of app engagement | The maximum, minimum and average length of time users interact with app | Interaction data will be collected continuously for up to 13 weeks for each participant. |
| Depth of app engagement | The maximum, minimum and average number of times users interact with specific app features after launching the app | Interaction data will be collected continuously for up to 13 weeks for each participant. |
| Acceptability of app and study procedures | All users will be invited to participate in a remote qualitative interview (up to 60 minutes). We do not expect that all participants will take part, and aim to recruit n=20 (10 in experimental group, 10 in control group). Interested users will be contacted via email to consent and arrange a suitable interview time. Semi-structured interviews will explore acceptability of the app and study procedures (i.e. affective attitude, burden, perceived effectiveness of the app, ethicality, app coherence, and opportunity costs) and usability of the app (informed by items on the System Usability Scale. | Interviews will take place after users have had the app installed on their device for 10 weeks after date of consent |
| D012216 |
| Rheumatic Diseases |
| D014987 | Xerostomia |
| D012466 | Salivary Gland Diseases |
| D009059 | Mouth Diseases |
| D009057 | Stomatognathic Diseases |
| D015352 | Dry Eye Syndromes |
| D007766 | Lacrimal Apparatus Diseases |
| D005128 | Eye Diseases |
| D003240 | Connective Tissue Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |